Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Aura A. J. van Esch, R Pauwels et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 21